CGP77675 (hydrate)

• Description:

  CGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively), and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity[1].

• UNSPSC:

  12352005

• Target:

  Src

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cgp77675-hydrate.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC1CCN(CCC2=CC=C(N3C=C(C4=CC=CC(OC)=C4)C5=C(N)N=CN=C53)C=C2)CC1.O.[x]

• Molecular Formula:

  C26H29N5O2.xH2O

• References & Citations:

  [1]Missbach M, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellularsubstrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999 May;24 (5) :437-49.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported